For 25 years, I've witnessed the profound impact of ESMO on nurturing the young generation of medical oncologists. Their unwavering support and inspiration are the pillars of our future in oncology. Let's continue to empower their bright minds 🌟 #FutureLeaders #MentorshipMatters

⏰ it's time to cast your vote 4 ESMO - Eur. Oncology #presidentialelection! G Curigliano MD PhD 's VISION & dedication to drive oncology to the next step: ✅A strongest focus on YOUNG 🌱 oncologists' training for success 👨🏻‍🏫 ✅A GLOBAL bandwidth 🌍 ✅A INNOVATOR to embrace the future of #oncology

There are moments when you have to take a position, this time was an easy one I voted for G Curigliano MD PhD Giuseppe Curigliano represents ESMO for me: Science and Education !! His commitment to OUR society is extraordinary and he has been an inspiration through years.

“Standing on the shoulders of Giants” Strong commitment towards nurturing the next generations of medical oncologists and researchers with the aim to improve cancer care globally 🌎 G Curigliano MD PhD Don’t forget to cast your vote for ESMO - Eur. Oncology President by tomorrow at noon CEST 👇

Siamo felici di comunicarvi che il Dr. Antonio Marra, Medico Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (IEO), Diretta dal Prof. Giuseppe Curigliano, è tra i sette italiani vincitori dell’ASCO Conquer Cancer Merit Award. 🏆 Per info👉shorturl.at/9uTK6

🇮🇹🇪🇺

I express my deepest gratitude to the ESMO - Eur. Oncology community, my esteemed colleagues, and friends for trusting me to serve as the next president of the Society. We are committed to dedicating all our efforts to advancing oncology and improving the lives of our patients.

This narrative review summarizes the literature supporting the use of PARP inhibitors for breast cancer treatment, as well as potential future research directions. ja.ma/4bGRXk0

Just out in EJC our analysis on safety and efficacy of new drugs investigated in phase I/II clinical trials by age ➡️Age, per se, should not represent a barrier when considering early-phase clinical trials as a treatment option doi.org/10.1016/j.ejca…

Impressive activity with the mutant-specific PI3K inhibitor RLY-2608

We mourn the untimely passing of Giovanni Scambia, a visionary leader in European gynecologic oncology. His pioneering contributions, dedication to patient care, and commitment to advancing research have left an indelible mark ESMO - Eur. Oncology ASCO

Finally out. This work is the result of a successful collaborative effort. Thanks to all contributors!

Grateful to ESMO - Eur. Oncology for the opportunity to share and promote our latest work. In this recent paper (👉 lnkd.in/dNVQbtMD), we present a comprehensive overview of the current applications of AI applied to cancer pathology and explore how this field is rapidly evolving

🔥 Annals of Oncology 🆙 ✅Artificial intelligence entering the pathology arena in oncology 🎯#AI enables automated tumour detection, classification, and biomarker identification with precision 🎙️ Antonio Marra #LCSM OncoAlert annalsofoncology.org/article/S0923-…

📢ESOncology masterclass for young investigators! 🎥Contents soon available online + submit a study proposal by July 6!💡 We will discuss live on Sept 25 the 4 selected! 👉e-eso.net/courses/25CC9#… Matteo Lambertini, MD PhD Evandro de Azambuja, MD, PhD Benjamin Besse Antonio Marra Saskia Litiere OncoAlert

Check out this review on #ArtificialIntelligence entering the pathology arena in oncology: current applications and future perspectives 🔓pubmed.ncbi.nlm.nih.gov/40307127/ ✍️Antonio Marra Stefania Morganti, MD Fresia Pareja Thomas J. Fuchs Anil Parwani G Curigliano MD PhD Caterina Marchiò

🆕Annals of Oncology podcast🎧: Artificial intelligence entering the pathology arena in oncology with Tom Powles and Antonio Marra tinyurl.com/m8dcm7ks To read the full article see doi.org/10.1016/j.anno…